DRRX Durect Corp
Price (delayed)
$0.7
Market cap
$21.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.27
Enterprise value
$12.92M
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic
Highlights
The company's quick ratio has surged by 184% QoQ and by 42% YoY
The debt has dropped by 89% year-on-year and by 84% since the previous quarter
Durect's equity has decreased by 38% YoY
The revenue has declined by 23% since the previous quarter and by 22% year-on-year
Key stats
What are the main financial stats of DRRX
Market
Valuations
Earnings
Shares outstanding
31.04M
Market cap
$21.73M
Enterprise value
$12.92M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.38
Price to sales (P/S)
10.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.36
Revenue
$2.03M
Gross profit
$1.95M
Operating income
-$18.91M
Net income
-$8.32M
EBIT
-$8.32M
EBITDA
-$8.24M
Free cash flow
-$19.09M
Per share
Balance sheet
Liquidity
EPS
-$0.27
EPS diluted
-$0.27
Free cash flow per share
-$0.62
Book value per share
$0.29
Revenue per share
$0.07
TBVPS
$0.5
Total assets
$18.35M
Total liabilities
$9.22M
Debt
$2.21M
Equity
$9.13M
Working capital
$5.47M
Debt to equity
0.24
Current ratio
1.71
Quick ratio
1.59
Net debt/EBITDA
1.07
Margins
Efficiency
Dividend
EBITDA margin
-405.7%
Gross margin
96.2%
Net margin
-409.8%
Operating margin
-931.2%
Return on assets
-30.7%
Return on equity
-140.6%
Return on invested capital
-412.8%
Return on capital employed
-78.2%
Return on sales
-409.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DRRX stock price
How has the Durect stock price performed over time
Intraday
0.19%
1 week
-6.13%
1 month
-17.55%
1 year
-20.77%
YTD
-6.67%
QTD
-12.72%
Financial performance
How have Durect's revenue and profit performed over time
Revenue
$2.03M
Gross profit
$1.95M
Operating income
-$18.91M
Net income
-$8.32M
Gross margin
96.2%
Net margin
-409.8%
The net income has soared by 70% YoY and by 51% from the previous quarter
The net margin has surged by 62% year-on-year and by 37% since the previous quarter
The company's operating income has surged by 52% YoY and by 15% QoQ
DRRX's operating margin is up by 39% YoY but it is down by 11% QoQ
Growth
What is Durect's growth rate over time
Valuation
What is Durect stock price valuation
P/E
N/A
P/B
2.38
P/S
10.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.36
The EPS has soared by 74% year-on-year and by 48% since the previous quarter
DRRX's P/B is 81% below its last 4 quarters average of 12.3 and 70% below its 5-year quarterly average of 7.9
Durect's equity has decreased by 38% YoY
The price to sales (P/S) is 28% lower than the last 4 quarters average of 14.8 and 20% lower than the 5-year quarterly average of 13.4
The revenue has declined by 23% since the previous quarter and by 22% year-on-year
Efficiency
How efficient is Durect business performance
The ROS has soared by 62% year-on-year and by 40% since the previous quarter
Durect's ROA has increased by 43% YoY and by 39% from the previous quarter
Durect's ROE has increased by 40% from the previous quarter and by 36% YoY
Durect's return on invested capital has increased by 29% QoQ
Dividends
What is DRRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DRRX.
Financial health
How did Durect financials performed over time
The total assets is 99% more than the total liabilities
The company's quick ratio has surged by 184% QoQ and by 42% YoY
DRRX's current ratio has soared by 141% since the previous quarter and by 34% year-on-year
The debt is 76% smaller than the equity
The debt to equity has dropped by 98% since the previous quarter and by 82% year-on-year
The debt has dropped by 89% year-on-year and by 84% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.